Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NervGen Pharma ( (TSE:NGEN) ) has issued an announcement.
NervGen Pharma announced positive preclinical results for its drug candidate NVG-291-R, which demonstrated significant functional recovery in models of traumatic hearing loss and peripheral nerve injury. These findings, presented at the 2025 Military Health System Research Symposium, highlight NVG-291’s potential to address debilitating conditions affecting military and civilian populations, reinforcing its broad therapeutic application and impact on nervous system repair.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$14.60 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
NervGen Pharma presents a high-risk, high-reward profile typical of early-stage biotech firms. Financial performance is weak due to ongoing R&D costs with no revenue, but technical indicators show positive momentum. Corporate events highlight potential upside from clinical advancements. However, the lack of earnings and reliance on financing remain significant concerns.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurologic disorders.
Average Trading Volume: 146,089
Technical Sentiment Signal: Buy
Current Market Cap: C$206.1M
For a thorough assessment of NGEN stock, go to TipRanks’ Stock Analysis page.